Tag Archive for ‘neoadjuvant therapy’

Figure 1. Overall schema of ALCHEMIST

In search of the philosopher’s stone: The ALCHEMIST study for lung cancer

This month’s column provides an update on the ALCHEMIST trials for patients with operable lung cancer, including the addition of a third arm to study, which permits the inclusion of patients without ALK or EGFR mutations.

Figure 1. ALCHEMIST schema

Biomarker-driven adjuvant targeted therapy for NSCLC—the ALCHEMIST trials

This month’s column summarizes the ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) platform and how it facilities definitive studies of adjuvant targeted therapies in biomarker-selected non-small cell lung cancer patients.

Neoadjuvant cancer therapy: Benefitting patients and improving cancer care

The rationale for neoadjuvant therapy is explored in this month’s column along with a summary of Alliance clinical trials involving this treatment.

Contact

Bulletin of the American College of Surgeons
633 N. Saint Clair St.
Chicago, IL 60611

Archives

Download the Bulletin App


Get it on Google Play